NanoViricides, Inc. — Form 10-Q Summary
Reporting period: Quarter and six months ended December 31, 2021 (fiscal 2022 second quarter); filed February 14, 2022. The filing identifies the company as a pre-revenue antiviral drug developer.
Financial results and position
| Metric | Three months ended Dec. 31, 2021 | Six months ended Dec. 31, 2021 | Prior-year comparable |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research and development expense | $1.26 million | $3.36 million | $1.49 million; $3.07 million |
| General and administrative expense | $0.66 million | $1.17 million | $0.80 million; $1.50 million |
| Net loss | $1.92 million | $4.53 million | $2.33 million; $4.64 million |
| Net loss per common share | $0.17 | $0.39 | $0.22; $0.44 |
| Operating cash used | Not stated for quarter | $2.84 million | $4.55 million for six months |
- Cash and cash equivalents were $17.34 million at December 31, 2021, down from $20.52 million at June 30, 2021. Six-month cash use included $0.21 million in property and equipment purchases; financing activities used $0.13 million.
- Total assets were $26.81 million, including net property and equipment of $8.94 million. Current liabilities were $344,285; the company reported no long-term debt and had repaid its $95,306 insurance-financing loan during the period.
- Stockholders’ equity was $26.47 million and accumulated deficit was $118.92 million. No meaningful operating margin is reported because the company has no revenue.
Changes versus prior comparable periods
- Quarterly net loss narrowed by about $0.41 million; six-month net loss narrowed by about $0.11 million. Quarterly R&D expense declined, while six-month R&D expense increased, primarily due to a $935,088 noncash Series A preferred-stock license milestone issued to related party TheraCour.
- Six-month operating cash use improved by about $1.71 million year over year. The prior-year period included $10.44 million of equity-financing proceeds; there were no comparable equity proceeds in the current period.
- Interest expense fell substantially following repayment of the CEO-related mortgage note in December 2020. Common shares outstanding rose from 11.52 million at June 30, 2021 to 11.53 million at December 31, 2021; preferred shares also increased.
Business outlook, risks and notable items
- The lead programs are COVID-19 candidates NV-CoV-2 and NV-CoV-2-R. The company said key preclinical safety work was completed and it was preparing regulatory submissions and clinical-trial plans; human trials had not begun. Management gave no firm trial-start timeline, citing regulatory, CRO, site, and other external dependencies.
- Management said existing resources were expected to fund planned operations through February 14, 2023, while also stating that further capital will be needed for longer-term operations and development. Clinical-trial spending is expected to increase; financing availability and timing are uncertain.
- Shingles candidate NV-HHV-101 is planned to follow the COVID-19 program. The company also has earlier-stage antiviral programs. Development and commercialization remain uncertain, and the company has no products, customers, or revenue.
- The September 2021 COVID-19 license with TheraCour, an entity controlled by CEO and Chairman Anil Diwan, includes preferred-share and cash milestones and a 15% royalty on net sales. The filing reports $166,948 of related-party accounts payable on the balance sheet, net of a $491,000 advance; the underlying TheraCour payable and offset are disclosed separately in the notes.
- Disclosure controls were deemed ineffective at December 31, 2021 because of an unremediated material weakness involving period-end review and personnel/resources. The company described a remediation committee. No pending or threatened legal proceedings were reported to its knowledge.
- Clinical and product claims discussed in the filing are based on preclinical studies and management’s expectations, not demonstrated human efficacy. The filing also identifies pandemic-related trial capacity and patient-enrollment constraints, reliance on TheraCour-licensed technology, and the need for additional financing.
Important facts for investors to verify
- Whether and when regulatory applications are submitted and accepted, and whether clinical trials actually commence.
- Cash burn, trial budgets, and the basis for management’s funding runway estimate; additional financing may be required.
- Terms, valuation, milestones, related-party balances, and potential dilution associated with the TheraCour licenses and preferred stock.
- Progress in remediating the material weakness in internal controls and whether controls are later assessed as effective.
- Clinical evidence supporting safety and efficacy claims, and the status of manufacturing, packaging, and required regulatory compliance.